©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Mar 8, 2017; 9(7): 349-351
Published online Mar 8, 2017. doi: 10.4254/wjh.v9.i7.349
Published online Mar 8, 2017. doi: 10.4254/wjh.v9.i7.349
Parkin in cancer: Mitophagy-related/unrelated tasks
Nabil Eid, Yoichi Kondo, Division of Life Sciences, Department of Anatomy and Cell Biology, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan
Author contributions: Eid N wrote the paper; Kondo Y critically reviewed it.
Conflict-of-interest statement: Eid N declares no conflict of interest related to this publication.
Correspondence to: Dr. Nabil Eid, Junior Associate Professor, Division of Life Sciences, Department of Anatomy and Cell Biology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan. nabil@osaka-med.ac.jp
Telephone: +81-72-6847197 Fax: +81-72-6846511
Received: December 21, 2016
Peer-review started: December 25, 2016
First decision: January 16, 2017
Revised: January 17, 2017
Accepted: February 8, 2017
Article in press: February 13, 2017
Published online: March 8, 2017
Processing time: 74 Days and 20.9 Hours
Peer-review started: December 25, 2016
First decision: January 16, 2017
Revised: January 17, 2017
Accepted: February 8, 2017
Article in press: February 13, 2017
Published online: March 8, 2017
Processing time: 74 Days and 20.9 Hours
Core Tip
Core tip: A large number of studies have found that the impaired Parkin function or downregulation of expression may induce cancer initiation and progression via mitophagy-related/unrelated mechanisms. Thus, there is a growing belief that Parkin may have tumor suppressor effects. Based on literature and on the authors’ recent publications regarding animal models of alcohol abuse, this paper highlights the various roles of Parkin in the suppression of oncogenesis. Proper understanding of Parkin functions may have therapeutic implications in the treatment of various cancers.